Data Dictionary: ZfkD Cancer Registry (Germany): Difference between revisions

From Beacon
No edit summary
No edit summary
Line 24: Line 24:
| Place of residence at diagnosis || "Place of residence at diagnosis, represented by 2-digit area code (""Bundesland"")" || 2-digit area code
| Place of residence at diagnosis || "Place of residence at diagnosis, represented by 2-digit area code (""Bundesland"")" || 2-digit area code
|-
|-
| Tumor diagnosis, ICD-10 code || ICD-10 diagnostic code of tumor || ICD-10, 4-digit code
| Tumour diagnosis, ICD-10 code || ICD-10 diagnostic code of tumour || ICD-10, 4-digit code
|-
|-
| Tumor diagnosis, ICD-10 version || ICD-10 version used to encode tumor diagnosis || ICD-10 version
| Tumour diagnosis, ICD-10 version || ICD-10 version used to encode tumour diagnosis || ICD-10 version
|-
|-
| Topography of tumor, ICD-O-3 code || Tumor site represented by ICD-O-3 topography code || ICD-O-3 (topography section) 4-digit code
| Topography of tumour, ICD-O-3 code || Tumour site represented by ICD-O-3 topography code || ICD-O-3 (topography section) 4-digit code
|-
|-
| Morphology of tumor, ICD-O-3 code || Morphology and behavior of tumor represented by 5-digit ICD-O-3 code. The fifth digit indicates tumor behavior (/0 benign; /1 uncertain; /2 carcinoma in situ; /3 malignant). || ICD-O-3 (morphology section), 5-digit code
| Morphology of tumour, ICD-O-3 code || Morphology and behavior of tumour represented by 5-digit ICD-O-3 code. The fifth digit indicates tumour behavior (/0 benign; /1 uncertain; /2 carcinoma in situ; /3 malignant). || ICD-O-3 (morphology section), 5-digit code
|-
|-
| Number of lymph nodes examined || Number of lymph nodes that were examined for the presence of cancer cells || (n) = number of lymph nodes
| Number of lymph nodes examined || Number of lymph nodes that were examined for the presence of cancer cells || (n) = number of lymph nodes
Line 36: Line 36:
| Number of lymph nodes affected || Number of lymph nodes that contain cancer cells || (n) = number of lymph nodes
| Number of lymph nodes affected || Number of lymph nodes that contain cancer cells || (n) = number of lymph nodes
|-
|-
| cTNM: T || Describes the size of the primary tumor. Staging according to tumor-specific TNM. || T stage, tumor-specific
| cTNM: T || Describes the size of the primary tumour. Staging according to tumour-specific TNM. || T stage, tumour-specific
|-
|-
| cTNM: N || Describes the degree of spread to regional lymph nodes. Staging according to tumor-specific TNM. || N stage, tumor-specific
| cTNM: N || Describes the degree of spread to regional lymph nodes. Staging according to tumour-specific TNM. || N stage, tumour-specific
|-
|-
| cTNM: UICC Stage || UICC Stage according to TNM. Describes the anatomical extent of disease. || UICC stage, tumor-specific
| cTNM: UICC Stage || UICC Stage according to TNM. Describes the anatomical extent of disease. || UICC stage, tumour-specific
|-
|-
| pTNM: T || Describes the size of the primary tumor. Staging according to tumor-specific TNM. || T stage, tumor-specific
| pTNM: T || Describes the size of the primary tumour. Staging according to tumour-specific TNM. || T stage, tumour-specific
|-
|-
| pTNM: N || Describes the degree of spread to regional lymph nodes. Staging according to tumor-specific TNM. || N stage, tumor-specific
| pTNM: N || Describes the degree of spread to regional lymph nodes. Staging according to tumour-specific TNM. || N stage, tumour-specific
|-
|-
| pTNM: UICC stage || UICC Stage according to TNM. Describes the anatomical extent of disease. || UICC stage, tumor-specific
| pTNM: UICC stage || UICC Stage according to TNM. Describes the anatomical extent of disease. || UICC stage, tumour-specific
|-
|-
| Other classification system: name || Name and/or type of other classification(s) used || e.g. Ann Arbor staging, WHO Classification of CNS Tumors, AJCC
| Other classification system: name || Name and/or type of other classification(s) used || e.g. Ann Arbor staging, WHO Classification of CNS Tumours, AJCC
|-
|-
| Other classification system: stage || Stage assigned based on other classification system || Stage
| Other classification system: stage || Stage assigned based on other classification system || Stage
Line 54: Line 54:
| Survival time || Time interval between incidence date and death || (n) = number of days
| Survival time || Time interval between incidence date and death || (n) = number of days
|-
|-
| Tumor size || Maximum diameter of invasive carcinoma (in mm) || (n) = tumor size in mm
| Tumour size || Maximum diameter of invasive carcinoma (in mm) || (n) = tumour size in mm
|-
|-
| DCIS size || Maximum diameter of ductal carcinoma in situ (in mm) || (n) = DCIS size in mm
| DCIS size || Maximum diameter of ductal carcinoma in situ (in mm) || (n) = DCIS size in mm
Line 68: Line 68:
| Gleason score || Gleason score || 2, 3, 4, 5, 6, 7, 7a, 7b, 8, 9 or 10
| Gleason score || Gleason score || 2, 3, 4, 5, 6, 7, 7a, 7b, 8, 9 or 10
|-
|-
| Tumor thickness || Thickness of tumor (mm) || (n) = thickness in mm
| Tumour thickness || Thickness of tumour (mm) || (n) = thickness in mm
|-
|-
| LDH level || LDH level (units per liter) || (n) = level in U/L
| LDH level || LDH level (units per liter) || (n) = level in U/L
Line 106: Line 106:
| Time to systemic therapy || Time interval between incidence date and systemic therapy start date (days) || (n) = number of days
| Time to systemic therapy || Time interval between incidence date and systemic therapy start date (days) || (n) = number of days
|-
|-
| Follow-up date || Date of most recent follow-up evaluation of tumor status || Date YYYY-MM-DD
| Follow-up date || Date of most recent follow-up evaluation of tumour status || Date YYYY-MM-DD
|-
|-
| TNM: T || Describes the size of the primary tumor. Staging according to tumor-specific TNM. || T stage, tumor-specific
| TNM: T || Describes the size of the primary tumour. Staging according to tumour-specific TNM. || T stage, tumour-specific
|-
|-
| TNM: N || Describes the degree of spread to regional lymph nodes. Staging according to tumor-specific TNM. || N stage, tumor-specific
| TNM: N || Describes the degree of spread to regional lymph nodes. Staging according to tumour-specific TNM. || N stage, tumour-specific
|-
|-
| TNM: UICC stage || UICC Stage at follow-up according to TNM. Describes the anatomical extent of disease. || UICC stage, tumor-specific
| TNM: UICC stage || UICC Stage at follow-up according to TNM. Describes the anatomical extent of disease. || UICC stage, tumour-specific
|-
|-
| Other classification system: name || Name and/or type of other classification(s) used || e.g. Ann Arbor staging, WHO Classification of CNS Tumors, AJCC
| Other classification system: name || Name and/or type of other classification(s) used || e.g. Ann Arbor staging, WHO Classification of CNS Tumours, AJCC
|-
|-
| Other classification system: stage || Stage assigned based on other classification system || Stage
| Other classification system: stage || Stage assigned based on other classification system || Stage
{| class="wikitable"
{| class="wikitable"
! Basis of diagnosis !! Describes how the tumor was identified !! "0 = death certificate only (DCO);  
! Basis of diagnosis !! Describes how the tumour was identified !! "0 = death certificate only (DCO);  
|-
|-
| 1 = clinical, ie physical exam only (no tumor-specific diagnostics);  ||  ||  
| 1 = clinical, ie physical exam only (no tumour-specific diagnostics);  ||  ||  
|-
|-
| 2 = clinical investigation using diagnostic techniques such as imaging, endoscopy, laparatomy, autopsy (no histopathology);  ||  ||  
| 2 = clinical investigation using diagnostic techniques such as imaging, endoscopy, laparatomy, autopsy (no histopathology);  ||  ||  
|-
|-
| 4 = specific tumor markers;  ||  ||  
| 4 = specific tumour markers;  ||  ||  
|-
|-
| 5 = cytology;  ||  ||  
| 5 = cytology;  ||  ||  
Line 130: Line 130:
| 6 = histopathology, metastasis;  ||  ||  
| 6 = histopathology, metastasis;  ||  ||  
|-
|-
| 7 = histopathology, primary tumor;  ||  ||  
| 7 = histopathology, primary tumour;  ||  ||  
|-
|-
| 9 = unknown"  ||  ||  
| 9 = unknown"  ||  ||  
|-
|-
| Tumor laterality || Describes which side of a paired organ is affected || "L = left;  
| Tumour laterality || Describes which side of a paired organ is affected || "L = left;  
|-
|-
| R = right;  ||  ||  
| R = right;  ||  ||  
Line 152: Line 152:
| Survival time || Time interval between incidence date and death || (n) = number of days  
| Survival time || Time interval between incidence date and death || (n) = number of days  
|-
|-
| Tumor size || Maximum diameter of invasive carcinoma (in mm) || (n) = tumor size in mm  
| Tumour size || Maximum diameter of invasive carcinoma (in mm) || (n) = tumour size in mm  
|-
|-
| DCIS size || Maximum diameter of ductal carcinoma in situ (in mm) || (n) = DCIS size in mm  
| DCIS size || Maximum diameter of ductal carcinoma in situ (in mm) || (n) = DCIS size in mm  
Line 202: Line 202:
| U = unknown"  ||  ||  
| U = unknown"  ||  ||  
|-
|-
| Tumor thickness || Thickness of tumor (mm) || (n) = thickness in mm  
| Tumour thickness || Thickness of tumour (mm) || (n) = thickness in mm  
|-
|-
| Ulceration || Indicates whether or not ulceration is present. || "J = Yes;  
| Ulceration || Indicates whether or not ulceration is present. || "J = Yes;  
Line 210: Line 210:
| LDH level || LDH level (units per liter) || (n) = level in U/L  
| LDH level || LDH level (units per liter) || (n) = level in U/L  
|-
|-
| Position || Rectal carcinoma: Distance between anocutaneous line and aboral tumor margin (in cm) || "(n) = distance from anocutaneous line in cm;  
| Position || Rectal carcinoma: Distance between anocutaneous line and aboral tumour margin (in cm) || "(n) = distance from anocutaneous line in cm;  
|-
|-
| U = unknown"  ||  ||  
| U = unknown"  ||  ||  

Revision as of 20:24, 25 August 2024

Go back to Database: ZfKD Cancer Registry (Germany) page.


Variable (English) Description Value range
Date of birth Patient's date of birth represented in international format YYYY-MM-DD. Date YYYY-MM-DD
Date of death or last known alive date Date of death (imputed) or last known alive date. For DCO cases, date of death = incidence date. Date YYYY-MM-DD
Other cause of death, ICD-10 code Other cause(s) of death as reported to the registry, ICD-10 code ICD-10 code
Other cause of death, ICD-10 version ICD-10 version used to encode other cause(s) of death ICD-10 version
Diagnosis date Date of incidence represented in international format YYYY-MM-DD. For DCO cases, incidence date = date of death. Date YYYY-MM-DD
Year of incidence Year of incidence. For DCO cases, year of incidence is equal to year of death. Date YYYY
Age at diagnosis Number of years between date of birth and date of diagnosis Age (years)
Place of residence at diagnosis "Place of residence at diagnosis, represented by 5-digit area code (""Kreiskennziffer"")" 5-digit area code
Place of residence at diagnosis "Place of residence at diagnosis, represented by 2-digit area code (""Bundesland"")" 2-digit area code
Tumour diagnosis, ICD-10 code ICD-10 diagnostic code of tumour ICD-10, 4-digit code
Tumour diagnosis, ICD-10 version ICD-10 version used to encode tumour diagnosis ICD-10 version
Topography of tumour, ICD-O-3 code Tumour site represented by ICD-O-3 topography code ICD-O-3 (topography section) 4-digit code
Morphology of tumour, ICD-O-3 code Morphology and behavior of tumour represented by 5-digit ICD-O-3 code. The fifth digit indicates tumour behavior (/0 benign; /1 uncertain; /2 carcinoma in situ; /3 malignant). ICD-O-3 (morphology section), 5-digit code
Number of lymph nodes examined Number of lymph nodes that were examined for the presence of cancer cells (n) = number of lymph nodes
Number of lymph nodes affected Number of lymph nodes that contain cancer cells (n) = number of lymph nodes
cTNM: T Describes the size of the primary tumour. Staging according to tumour-specific TNM. T stage, tumour-specific
cTNM: N Describes the degree of spread to regional lymph nodes. Staging according to tumour-specific TNM. N stage, tumour-specific
cTNM: UICC Stage UICC Stage according to TNM. Describes the anatomical extent of disease. UICC stage, tumour-specific
pTNM: T Describes the size of the primary tumour. Staging according to tumour-specific TNM. T stage, tumour-specific
pTNM: N Describes the degree of spread to regional lymph nodes. Staging according to tumour-specific TNM. N stage, tumour-specific
pTNM: UICC stage UICC Stage according to TNM. Describes the anatomical extent of disease. UICC stage, tumour-specific
Other classification system: name Name and/or type of other classification(s) used e.g. Ann Arbor staging, WHO Classification of CNS Tumours, AJCC
Other classification system: stage Stage assigned based on other classification system Stage
Survival time Time interval between incidence date and death (n) = number of days
Tumour size Maximum diameter of invasive carcinoma (in mm) (n) = tumour size in mm
DCIS size Maximum diameter of ductal carcinoma in situ (in mm) (n) = DCIS size in mm
PSA level PSA level (ng/mL) (n) = level in ng/mL
PSA level date Date of PSA blood test Date YYYY-MM-DD
Gleason: primary grade Primary Gleason grade 1, 2, 3, 4 or 5
Gleason: secondary grade Secondary Gleason grade 1, 2, 3, 4 or 5
Gleason score Gleason score 2, 3, 4, 5, 6, 7, 7a, 7b, 8, 9 or 10
Tumour thickness Thickness of tumour (mm) (n) = thickness in mm
LDH level LDH level (units per liter) (n) = level in U/L
Surgery date Surgery date represented in ISO 8601 format YYYY-MM-DD. Year and month of surgery are collected from registries, day of surgery is assigned an arbitrary value. Date YYYY-MM-DD
Surgery type OPS code of surgery OPS code
OPS version OPS version used to encode surgery type OPS version number
Time to surgery Number of days between diagnosis and surgery (n) = number of days
Radiotherapy start date Radiotherapy start date Date YYYY-MM-DD
Percutaneous radiotherapy - Stereotactic Indicates if percutaneous radiotherapy (external beam radiotherapy) was applied using stereotactic techniques. ST = stereotactic
Percutaneous radiotherapy - Respiratory-gated Indicates if percutaneous radiotherapy (external beam radiotherapy) was respiratory-gated. 4D = respiratory-gated
Radiotherapy duration Number of days between diagnosis and surgery (n) = number of days
Time to radiotherapy Time interval between incidence date and radiotherapy start date (days) (n) = number of days
Systemic therapy drug Medication(s) used for systemic therapy. Multiple medications require separate entries. Name or: ATC code + ATC version
Systemic therapy protocol type Systemic therapy protocol name or code. "Name or: protocol code
Systemic therapy protocol Systemic therapy protocol code. Suggested guidance: https://plattform65c.atlassian.net/wiki/spaces/UMK/pages/15532519/Protokolle
Systemic therapy protocol Systemic therapy protocol name (name) = protocol name
Systemic therapy protocol Systemic therapy protocol version (version) = protocol version
Systemic therapy start date Systemic therapy start date Date YYYY-MM-DD
Systemic therapy duration Systemic therapy duration (days) (n) = number of days
Time to systemic therapy Time interval between incidence date and systemic therapy start date (days) (n) = number of days
Follow-up date Date of most recent follow-up evaluation of tumour status Date YYYY-MM-DD
TNM: T Describes the size of the primary tumour. Staging according to tumour-specific TNM. T stage, tumour-specific
TNM: N Describes the degree of spread to regional lymph nodes. Staging according to tumour-specific TNM. N stage, tumour-specific
TNM: UICC stage UICC Stage at follow-up according to TNM. Describes the anatomical extent of disease. UICC stage, tumour-specific
Other classification system: name Name and/or type of other classification(s) used e.g. Ann Arbor staging, WHO Classification of CNS Tumours, AJCC
Other classification system: stage Stage assigned based on other classification system Stage
Basis of diagnosis Describes how the tumour was identified "0 = death certificate only (DCO);
1 = clinical, ie physical exam only (no tumour-specific diagnostics);
2 = clinical investigation using diagnostic techniques such as imaging, endoscopy, laparatomy, autopsy (no histopathology);
4 = specific tumour markers;
5 = cytology;
6 = histopathology, metastasis;
7 = histopathology, primary tumour;
9 = unknown"
Tumour laterality Describes which side of a paired organ is affected "L = left;
R = right;
B = bilateral;
M = center;
U = unknown;
T = not applicable (e.g., systemic disease)"
Death certificate notified (DCN) Indicates whether or not the case was first notified by death certificate (official cause of death). "J = Yes;
N = No"
Survival time Time interval between incidence date and death (n) = number of days
Tumour size Maximum diameter of invasive carcinoma (in mm) (n) = tumour size in mm
DCIS size Maximum diameter of ductal carcinoma in situ (in mm) (n) = DCIS size in mm
Menopausal status Menopausal status before initiation of treatment. Postmenopausal = time since last menstruation > 1 year OR E2 and FSH within postmenopausal range. "1 = premenopausal (includes perimenopausal);
3 = postmenopausal;
U = unknown"
Estrogen receptor status Estrogen receptor status according to immunoreactivity score (IRS) "P = positive (IRS >= 1);
N = negative;
U = unknown"
Progesterone receptor status Progesterone receptor status according to immunoreactivity score (IRS) "P = positive (IRS >= 1);
N = negative;
U = unknown"
HER2 status HER2 (ERBB2) status "P = positive (ICH+++ or: ICH++ and positive ISH);
N = negative;
U = unknown"
PSA level PSA level (ng/mL) (n) = level in ng/mL
PSA level date - accuracy Indicates if only year is accurate (M), if year and month are accurate (T), or if year and month are estimated (V). Please note: Day is not collected from registries and assigned an arbitrary value (usu. 15) by ZfKD. "M = year is accurate, month is estimated;
T = year and month are accurate;
V = year and month are estimated"
PSA level date Date of PSA blood test Date YYYY-MM-DD
Gleason: primary grade Primary Gleason grade 1, 2, 3, 4 or 5
Gleason: secondary grade Secondary Gleason grade 1, 2, 3, 4 or 5
Gleason score Gleason score 2, 3, 4, 5, 6, 7, 7a, 7b, 8, 9 or 10
Gleason score: sampling method Describes tissue sampling method/origin of tissue sample used to determine Gleason score. "O = prostatectomy;
S = punch biopsy;
U = unknown"
Tumour thickness Thickness of tumour (mm) (n) = thickness in mm
Ulceration Indicates whether or not ulceration is present. "J = Yes;
N = No"
LDH level LDH level (units per liter) (n) = level in U/L
Position Rectal carcinoma: Distance between anocutaneous line and aboral tumour margin (in cm) "(n) = distance from anocutaneous line in cm;
U = unknown"
KRAS mutation Indicates presence of KRAS proto-oncogene mutations "W = wild type;
M = mutation;
U = unknown;
N = not assessed"
Surgery date - accuracy Indicates if only year is accurate (M), if year and month are accurate (T), or if year and month are estimated (V). Please note: Day is not collected from registries and assigned an arbitrary value (usu. 15) by ZfKD. "M = year is accurate, month is estimated;
T = year and month are accurate;
V = year and month are estimated"
Surgery date Surgery date represented in ISO 8601 format YYYY-MM-DD. Year and month of surgery are collected from registries, day of surgery is assigned an arbitrary value. Date YYYY-MM-DD
Surgery type OPS code of surgery OPS code